Diseases, Conditions, Syndromes

Efpeglenatide lowers risk for adverse CV events in T2DM

(HealthDay)—For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk for adverse cardiovascular events is lower with efpeglenatide, an exendin-based glucagon-like peptide ...

page 1 from 28